AUDIO: What COA said about the application in 2019 to FDA for clinical trials of COA 72 as an anti-HIV drug

When the Parliamentary Select Committee on Health visited and what COA said about the application in 2019 to FDA for clinical trials of COA 72 as an anti-HIV drug in 2019 and the payment of $5000 registration.

Dr Caleb Mawuli Agbale, the Product Manager briefed the committee members on the operations of COA and the product.

• Related articles
• Parliamentary Select Committee on Health pledges advocacy support for COA RMCL’s research
• FDA Ghana’s disclaimer on purported approval of COA 72 for clinical trials as an anti-HIV drug
• COA Research and Manufacturing Limited Company sets record straight on Coa-72 clinical trials